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CONSCIOUS SEDATION MEDICATION CHOICE DOES NOT AFFECT 
OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT. 
 
Diane R.M. Somlo, Syed Usman Bin Mahmood, Makoto Mori, Qingbing Zhu, John K. 
Forrest, and Abeel A. Mangi. Section of Cardiac Surgery, Department of Surgery, Yale 
University School of Medicine, New Haven, CT. 
 
Conscious Sedation (CS) has become a mainstay option for anesthesia in Transcatheter 
Aortic Valve Replacement (TAVR), but there has been limited investigation into the effect 
of CS medication choice on patient outcomes. This study aimed to assess whether the CS 
medications used in TAVR were associated with primary outcomes, including hospital 
length of stay (LOS), mortality, or need for post-operative permanent pacemaker. This 
retrospective, observational study included 272 patients who underwent TAVR with CS at 
a tertiary teaching hospital between September 2014 and December 2017. Patient and 
procedure data were collected from the STS/ACC Transcatheter Valve Therapy Registry 
and chart review. Patients were grouped according to the CS medications they received 
during TAVR, and three analyses were conducted from the pool of 272 patients: Propofol 
versus No propofol (n=203 vs. n=64), Propofol plus midazolam versus Propofol only (n=70 
vs. n=94), and Dexmedetomidine versus No dexmedetomidine (n=86 vs. n=186). Several 
patient and procedure characteristics differed significantly at baseline in all three analyses. 
Regression and Cox proportional hazard analyses were conducted to adjust for differences. 
After adjustment, primary outcomes were not significantly different in each analysis, and 
there were no differences in secondary outcomes, including in-hospital death, discharge 
location, creatinine change, hemoglobin change, discharge creatinine, and incidence of 
blood transfusion. Among patients with prolonged LOS, more patients in the Propofol plus 
midazolam group had hypotension as a causative factor compared to the Propofol only 





younger and less ill. Ultimately, it is unclear whether CS medication choice for TAVR 
affects patient outcomes, and it is possible that medication selection can be left to provider 
preference. Further analysis with larger sample sizes may be warranted, especially to study 
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Aortic stenosis (AS) is the most prevalent valvular disease in developed countries,1 
affecting an estimated 12-13% of patients who are > 75-years old.2 In the United States 
alone, an estimated 2.5 million people over the age of 75 suffer from AS.3 AS patients are 
sub-classified into “at risk,” “progressive,” or “severe” based on diagnostic criteria 
including patent valve area, pressure gradient, maximum aortic velocity, ventricular 
dysfunction, and other measures.4,5 It is estimated that more than 25% of all current AS 
cases are severe, and the number of severe AS cases increases year over year; an estimated 
27,000 patients newly meet criteria for severe AS annually.2 Severe AS can either be 
asymptomatic (~25%) or symptomatic (~75%),2 and symptoms include exertional dyspnea 
and angina, sequelae of heart failure, and syncope or presyncope.5 Without treatment, 
roughly 50% of symptomatic, severe AS patients die within 2 years, and the prognosis 
continues to worsen thereafter.6-9 Since there is no medical therapy available for severe 
AS, replacement of the diseased valve is crucial. Replacement can be accomplished by 
either Surgical Aortic Valve Replacement (SAVR) or by Transcatheter Aortic Valve 
Replacement (TAVR; Transcatheter Aortic Valve Implantation, TAVI).  
While SAVR was the historical mainstay for treatment of severe, symptomatic AS, 
TAVR has taken off as the less invasive and increasingly popular alternative. The pool of 
TAVR-eligible patients has expanded rapidly over the last five years; in the United States, 
the Food and Drug Administration (FDA) first approved TAVR for severe AS patients who 
are at high surgical risk in 2015.10-13 Studies then demonstrated that TAVR is non-inferior 
for intermediate-risk surgical patients as well,14-17 and the FDA subsequently expanded 





randomized trial demonstrated noninferiority of TAVR versus SAVR even for low-risk 
surgical patients with severe AS.18 About three months later, TAVR was FDA-approved 
for use in low-risk surgical candidates.19-21 With this dramatic increase in TAVR eligibility, 
the increasing global elderly population, and high prevalence of AS and severe AS, the 
number of TAVR procedures conducted annually is likely to continue increasing. 
 
Conscious Sedation in TAVR 
Earlier in the adoption of TAVR, the procedure was exclusively completed with 
patients under General Anesthesia (GA). However, as procedural knowledge has grown 
over the last decade, there has been a paradigm shift in anesthetic approach: Conscious 
Sedation (CS, also known as Moderate Sedation or Monitored Anesthesia CareA) has 
emerged as the viable alternative to GA. GA and CS represent different depths of sedation 
along the continuum of sedation.22 GA is the deepest sedation possible, where patients are 
totally unresponsive to painful stimuli and require ventilation support. Conversely, CS 
consists of local anesthesia and parenteral medications that induce a state of depressed 
consciousness with anxiolysis and pain management. Unlike GA, CS does not require 
airway intervention, and patients are able to respond purposefully to tactile and verbal 
stimulation. CS generally results in less physiologic disturbance than GA, which typically 
leads to faster recovery times and decreased hospital length of stay.23  
Indeed, the proportion of TAVR procedures completed under CS has been 
increasing. From 2013 to 2019, the percentage of transfemoral-access TAVR procedures 
performed under CS rather than GA went from 33% to 64%.24 The increase in use of CS 
 
A Per the American Society of Anesthesiologists, CS is termed “Monitored Anesthesia Care” (MAC) when 





was likely bolstered by multiple observational and meta-analysis studies that demonstrated 
CS in TAVR results in equivalent procedure efficacy, shorter hospital stays, decreased ICU 
time, and decreased total cost of care compared to GA.25-31 There has only been one 
prospective study to date that has compared TAVR outcomes after randomizing patients to 
GA or CS (SOLVE-TAVI), and this randomized study also found that CS resulted in 
equivalent outcomes, including mortality, stroke, myocardial infarction, paravalvular leak, 
and hospital and intensive care unit length of stay.32 Additionally, the authors found that 
CS resulted in decreased use of inotropic agents compared to GA. Overall, anesthesia 
during TAVR has trended towards a minimalist approach with lighter sedation, and it is 
likely that CS will be an increasingly popular choice for anesthesia in TAVR. 
 
Which Conscious Sedation medication regimen is optimal for TAVR? 
The three most common sedatives for CS are propofol, midazolam, and 
dexmedetomidine, which are usually combined with opioids such as fentanyl and 
remifentanil for analgesia.33 Each medication has benefits of use as well as potential 
adverse respiratory and hemodynamic effects: 
• Propofol is a sedative-hypnotic that provides limited analgesia,34 and it is the preferred 
agent for sedation in interventional procedures largely because of its rapid onset and 
short half-life, which allows it to be easily titrated and stopped for smooth recovery.35 
However, propofol also causes dose-dependent respiratory depression and 
cardiovascular depression that requires close monitoring,22 and propofol is more likely 






• Midazolam is a benzodiazepine with both anxiolytic and anterograde amnesia effects.34 
Like propofol, midazolam also does not offer analgesia and is usually paired with an 
opioid. Midazolam is also a dose-dependent respiratory depressant, and it has 
cardiovascular depressant effects, although these are usually minimal. Both the 
respiratory and cardiac depression effects increase when midazolam is co-administered 
with opioids or other sedatives.33 Midazolam and other benzodiazepines can be 
reversed using flumazenil,36 but propofol does not have a reversal agent. 
• Dexmedetomidine is an alpha-2 adrenergic receptor agonist which, unlike propofol or 
midazolam, offers analgesia in addition to anxiolysis and sedation.34 Dexmedetomidine 
causes minimal respiratory depression, and unlike propofol and midazolam, it does not 
synergize with other sedatives and opioids. However, it can induce both severe 
bradycardia and transient hypertension as a result of its sympatholytic effects.33 There 
are no reversal agents currently available for human use. 
Even though CS is widely used for TAVR, it remains unclear whether a certain CS 
medication regimen is more or less suited for TAVR patients. CS medications may not 
usually be expected to influence patients’ clinical course beyond the procedure and 
immediately post-procedure, but there are several reasons why sedative choice may have a 
greater impact on clinical trajectory for TAVR patients. First, TAVR patients are overall 
elderly and therefore more sensitive to sedatives. Among low-surgical risk TAVR patients, 
the average age was 73,18 and the average age for intermediate-risk patients was 82.15 
Geriatric patients are more sensitive to CS medication’s intended effects and adverse side 
effects,33 and they are more susceptible to over-sedation.34 Consequently, it is recognized 





response, and it may be more difficult to avoid sedative-associated complications in these 
patients.  
Second, the conditions that render patients eligible for TAVR likely increases their 
sensitivity to adverse cardiovascular and respiratory effects of sedatives and makes it more 
difficult to avoid these complications. Patients must have severe aortic valve disease and a 
degree of symptomatic heart failure or measurable left ventricular dysfunction to be 
eligible for TAVR,4 and these conditions result in a more friable hemodynamic system that 
is likely  more vulnerable to CS medication-induced hemodynamic perturbations. Indeed, 
propofol, dexmedetomidine, and midazolam all decrease systemic vascular resistance, and 
this creates particular risk of hypotension in patients with AS; the stenotic valve is a fixed 
obstruction that causes decreased cardiac output, and decreased output drives myocardial 
hypoperfusion and decreased left ventricular contractility.37 Furthermore, both propofol 
and dexmedetomidine are identified as agents that can exacerbate myocardial dysfunction 
and precipitate or worsen heart failure symptoms.38 While completion of TAVR would 
address the valvular dysfunction and have an immediate effect on the patient’s 
cardiovascular function, complications could still arise prior to valve replacement or occur 
despite the replacement due to advanced age or frailty. 
Overall, increased risk of sedation-associated complications for these patients 
means there is increased risk that sedation choice could affect clinical course and longer-
term outcomes for TAVR patients. If a patient experiences over-sedation intra-operatively, 
they may need intubation to address respiratory depression or pressor support and intensive 
care unit monitoring for persistent hemodynamic instability. Both outcomes after TAVR 





stay greater than 72 hours) for TAVR patients is an independent predictor of 1-year all-
cause mortality.39 Ultimately, there is need to ascertain whether a given CS medication 
combination is associated with better or worse outcomes following TAVR, because this 
population has factors that increase risk of complications from sedation. If CS medications 
do affect outcomes even marginally, medication adjustments could lead to improvement of 
outcomes on an aggregate level due to the large number of TAVR operations conducted 
with CS annually. 
To date, there are four studies that explore the effect of specific CS medications on 
patient outcomes after TAVR, and all four studies focus primarily on propofol versus 
dexmedetomidine. First, in 2016, Khalil et al. conducted a pilot study that randomized 50 
patients to receive propofol (n=25) or dexmedetomidine (n=25) as CS agents for TAVR.40 
Authors found that both propofol and dexmedetomidine provided adequate sedation but 
that the dexmedetomidine patients had more intra-operative hemodynamic instability: 
patients treated with dexmedetomidine had significantly lower intra-operative heart rate 
and mean arterial blood pressure and required more phenylephrine boluses. However, 
authors found no differences between the group’s post-operative complications, including 
hospital length of stay, ICU length of stay, mortality, renal failure, stroke, pulmonary 
edema, peripheral ischemia, local infection, ventricular arrhythmias, and myocardial 
ischemia.  
Second, Mayr et al. compared propofol-opioid (n=150) versus dexmedetomidine  
only (n=157) in a retrospective analysis of TAVR CS regimens in 2017.41 However, this 
study focused exclusively on outcomes relating to intra-operative hemodynamics and peri-





outcomes and complications. Mayr et al. found that the dexmedetomidine patients had 
significantly lower arterial partial pressure of carbon dioxide, lower frequency of 
hypercapnia, and lower need for norepinephrine than the propofol group. It was noted that 
conversion to GA occurred more frequently in the propofol group compared to the 
dexmedetomidine group, but the difference was not statistically significant.  
Third, Chen et al. conducted a single institution, retrospective study in 2017 to 
compare propofol only (n=39) versus dexmedetomidine plus propofol (n=34).42 The 
authors considered both post-operative outcomes and the effect of patient age on average 
dose. They found no significant difference between the groups, including in incidence of 
conversion to GA, total procedure time, incidence of post-operative delirium, hospital 
length of stay, and intensive care unit length of stay. Additionally, they found no 
association between patient age group and the doses of medications used.  
Lastly, Kronfli et al. conducted a single institution, prospective observational study 
in 2020 to investigate outcomes and costs after TAVR with propofol (n=58) versus 
dexmedetomidine (n=103).43 This was the only study to compare costs for these agents, 
and dexmedetomidine is typically a more costly agent than propofol. As was the case for 
the prior studies, the authors also found no significant difference in post-operative 
outcomes including in-hospital mortality, complication rate, need for pressors, and total 
cost of hospitalization. This was the largest study to date that considered outcomes (i.e., 
excluding Mayr et al.), but even this study cited small sample size as a key limitation.  
While these four studies have helped get closer to identifying whether a given CS 
regimen is better for TAVR, the question remains open in several respects. First, these 





dexmedetomidine. However, there are other CS medication combinations that are currently 
in use in TAVR that are yet to be investigated for this procedure. For instance, no study 
has considered the effect of combination propofol plus midazolam versus propofol alone 
or midazolam alone in TAVR. For comparison, the combination of propofol plus 
midazolam has been studied for other procedures, including colonoscopy,44-46 endoscopic 
procedures,47-49 and pediatric sedation for MRI.50 These studies found some differences 
between the comparators, with most finding that propofol plus midazolam resulted in 
deeper sedation and a longer recovery period. This could have implications for TAVR 
patient recovery and should be investigated further. 
Second, while these studies found no significant difference in post-operative 
outcomes thus far, it is still possible that a difference exists but has not been detected. Of 
the studies that considered post-operative outcomes (Khalil et al., Chen et al., and Kronfli 
et al.), all three cited small sample size as a key limitation for the analyses. All three studies 
also specifically noted that complications of interest occurred at a very low rate and led to 
analyses that were underpowered. As a result, there is need to investigate CS medications 
using larger sample sizes to identify any differences that may previously have been 






STATEMENT OF PURPOSE 
We set out to investigate whether a given CS regimen of interest is associated with 
better or worse post-TAVR outcomes, with primary focus on total hospital length of stay 
(LOS), mortality, and need for post-operative permanent pacemaker. Incidence of post-
operative permanent pacemaker (PPM) is also a key outcome of interest, because while 
other post-TAVR complications have decreased with time, incidence of post-operative 
PPM has paradoxically increased51 and could be affected by CS choice, especially 
propofol52 or dexmedetomidine.53 
Medication Groups and Hypotheses 
First, we set out to test whether CS with either propofol or propofol plus 
midazolam could lead to worse outcomes after TAVR. Both propofol and 
benzodiazepines cause respiratory depression, especially if they are co-administered,33,54 
and respiratory depression is the most common complication of CS.33 Indeed, in a 2006 
analysis of claims data, over half of the patients who experienced respiratory depression 
and associated complications after CS had received propofol with or without a 
benzodiazepine.55 Furthermore, geriatric patients are more susceptible to the adverse 
effects of propofol and midazolam.33 As a result, these CS medications may lead to 
increased risk of over sedation, which could potentially lengthen hospital stay and lead to 
increased related post-procedural complications such as conversion to GA or in-hospital 
death.  
There is also evidence that propofol may provide less adequate post-operative 
pain amelioration and may lead to increased need for post-operative pain management 





surgery found that propofol resulted in worse intraoperative analgesia and higher pain 
scores post-operatively.56 Another randomized trial studying the effect of propofol versus 
dexmedetomidine following total knee arthroplasty with spinal anesthesia and CS found 
that propofol patients required increased post-operative opioids.57 Post-operative pain and 
increased opioids both increase risk of delirium,58 which is of concern for this majority 
geriatric patient population and could prolong hospital stay. Overall, investigation of the 
effect of propofol and propofol plus midazolam on TAVR outcomes is warranted and 
will be explored via the following analyses: 
 
• Hypothesis A: Use of propofol for CS in TAVR, regardless of other medications 
used, is associated with worse outcomes (longer LOS, increased hazard of mortality, 
or increased need for post-operative PPM). Analysis A will compare outcomes after 
CS with Propofol versus CS with No propofol. 
• Hypothesis B: CS in TAVR with propofol plus midazolam will be associated with 
worse outcomes than CS with propofol only. Analysis B will be a comparison of 
outcomes after Propofol plus midazolam versus Propofol only. 
 
Second, we set out to investigate whether dexmedetomidine use is associated with 
better outcomes after TAVR. While both Khalil et al. and Mayr et al. found that 
dexmedetomidine resulted in lower intra-operative blood pressures, neither study 
demonstrated worse dexmedetomidine outcomes. In fact, there are several reasons why 
dexmedetomidine may be potentially beneficial for post-operative outcomes. First, a  2019 
meta-analysis that found dexmedetomidine may reduce incidence of delirium after cardiac 





compared to propofol56,60 and overall reduced risk of acute kidney injury.61,62 Use of 
dexmedetomidine is also associated with reduced risk of intra-operative respiratory 
depression compared to CS with benzodiazepines or propofol with opioids.63 Indeed, in a 
study of patients undergoing endoscopic retrograde cholangiopancreatography (ERCP), 
patients treated with dexmedetomidine plus ketamine rather than propofol plus opioids 
experienced significantly fewer adverse sedation-related events.64  Additionally, there is 
some evidence that dexmedetomidine could reduce risk of arrythmias, but this evidence is 
mixed.53,65,66 Overall, dexmedetomidine could potentially benefit the TAVR patient 
population due to its effects on these common post-procedural complications and will be 
investigated by the following analysis: 
• Hypothesis C: Use of dexmedetomidine in CS for TAVR, regardless of other 
medications, will be associated with improved outcomes. Analysis C will compare 







Author D. Somlo wrote, submitted, achieved approval, and re-submitted the protocol for 
re-approval as necessary. This study received approval from the Institutional Review Board 
(Protocol #2000021153), and individual patient consent was waived, as this was a 
retrospective analysis.  
 
Ethics Statement 
There were no ethical concerns related to this study, and the entirety of the study was 
conducted in accordance with the approved protocol. 
 
Patients 
The study population included all patients who underwent TAVR for the treatment of 
severe Aortic Stenosis with plan for conscious sedation at Yale New Haven Hospital (New 
Haven, Connecticut) between September 2014 and December 2017. All patients were 
evaluated by the Structural Heart Disease Team and were determined to be candidates for 




To identify patients in this cohort, D. Somlo requested patient medical record numbers 
from the institutional Joint Data Analytics Team. Following review board approval of the 
protocol, the Joint Data Analytics Team provided the record numbers and accompanying 





recorded for the Society of Thoracic Surgery (STS)/American College of Cardiology TVT 
Registry. D. Somlo and Usman Bin Mahmood, MBBS, then completed manual chart 
review using the healthcare system’s electronic medical record system, EPIC, to verify and 
update all data using definitions from the STS/ACC TVT Registry v2.0 Coder’s Data 
Dictionary. D. Somlo completed further chart review to clarify the cause of intraprocedural 
conversion to general anesthesia, intraprocedural conversion to surgery, or hospital length 
of stay greater than 3 days. 
 
Mortality Data Collection 
D. Somlo requested and obtained patient mortality data up to February 1, 2020 from both 
chart review and from the Connecticut Department of Public Health. D. Somlo requested 
records from the Connecticut Department of Public Health for January 2014 and December 
2018. The state records were checked against each patient’s corresponding medical record 
in EPIC to verify the mortality outcomes and dates. If a death was recorded in the state 
records but not in EPIC, the state record was used. Conversely, if a patient was recorded 
as deceased in EPIC but not in the state data, the EPIC data was used. 14 of the 60 deceased 
patients (23%) were not recorded in the state records, because they were either not 
Connecticut residents or passed after December 2018.  
 
Risk Score Calculation 
Of the 277 patients included in the analyses, 8 patients did not have STS Risk of Mortality 
Scores in their charts. For these patients, D. Somlo calculated STS Risk of Mortality using 





through chart review: age, sex, height, weight, current dialysis, hypertension, 
immunocompromised status, prior peripheral arterial disease, prior cerebrovascular disease 
or stroke, diabetes, chronic lung disease, smoking status, use of home oxygen, prior 
Coronary Artery Bypass Grafting (CABG), prior Percutaneous Coronary Intervention 
(PCI), prior aortic valve replacement, prior Myocardial Infarction, New York Heart 
Association (NYHA) heart failure score from the prior 2 weeks, Coronary Artery Disease 
(CAD) presenting symptoms, prior cardiogenic shock, pre-existing atrial fibrillation or 
atrial flutter, pre-existing conduction defect, number of diseased coronary vessels, previous 
permanent pacemaker, previous implantable cardioverter-defibrillator, status of TAVR 
(elective, urgent, emergent), and prior cardiac arrest. 
 
Dose calculations 
To normalize medication doses for comparison, D. Somlo used the same approach as Chen 
et al.42 First, chart review was completed to obtain total quantities of each medication 
administered intraoperatively. Each medication quantity was then divided by each patient’s 
mass (kg) and length of procedure (hours) to obtain dose in units of mcg/kg/hour or 
mg/kg/hour.  
 
Statistical Analysis and Figures 
All statistical testing for this study was completed by D. Somlo, with assistance and support 
from Makoto Mori, MD. Summary statistics of baseline patient characteristics, procedural 
characteristics, and procedure outcomes and the multivariable linear and logistic regression 





Diego, CA, United States). Cox proportional hazard analyses were completed in Stata 15.0 
(StataCorp, College Station, TX, United States). An alpha of 0.05 was used as the cut-off 
for significance, and all comparisons were two-sided. Descriptive statistics for continuous 
variables were reported as mean with standard deviation, and categorical variables were 
reported as count (percentage). For statistical comparison tests, continuous variables were 
analyzed with ANOVA, and categorical variables were analyzed via Chi-square tests. For 
comparisons of continuous variable distributions (cases over time, drug dose comparisons), 
Kolmogorov-Smirnov tests were conducted. An outlier for length of stay was identified 
using outlier analysis in GraphPad Prism (shown in Fig. 4). The outlier was only excluded 
from regression analysis of hospital length of stay. All figures were generated by D. Somlo. 
All figures were created using GraphPad Prism, with the exception of the Sankey diagram 
(Fig. 1) generated using free online software, SankeyMATIC 






Patient CS medication groups are shown in Fig. 1. A total of 706 TAVR patients 
were identified. 61% of patients (n=429) were treated with GA and were excluded. At the 
study institution, CS is conducted by anesthesiology trainees and attending physicians for 
TAVR. Per the American Society of Anesthesiologists, CS administered by an 
anesthesiologist is referred to as “Monitored Anesthesia Care” (MAC), so CS will be 





39% of TAVR cases (n=277) were completed under MAC. MAC patients were 
treated with three main sedatives – propofol, midazolam, or dexmedetomidine – as well as 
opioids (fentanyl and remifentanil). 5 of the 277 MAC patients were treated with unique 
medications: hydromorphone (n=3), morphine (n=1), or ketamine (n=1). These 5 patients 
were excluded from further analysis. Additionally, it was noted during chart review that 
Figure 1: Sankey Diagram of patient exclusion and grouping. 272 of the 277 Conscious 
Sedation patients were included in further analysis. Analyses A, B, and C examine different 
combinations of the identified medication subgroups at the far right. MAC, Monitored 





many patients received lidocaine for local anesthesia, but lidocaine use and doses were not 
considered. Three separate analyses were conducted from this pool of MAC patients to 
assess characteristics and outcomes associated with different medication groups: Propofol 
versus No Propofol (Analysis A), Propofol plus midazolam versus Propofol only (Analysis 
B), and Dexmedetomidine versus No Dexmedetomidine (Analysis C).  
 
Analysis A: Propofol versus No Propofol 
272 CS patients were grouped based on whether or not they received propofol as 
part of their MAC treatment. n=5 patients received a dose of propofol that was likely 
subtherapeutic (<20mg total) and were excluded from both groups. The remaining 267 
patients were divided into the Propofol group (n=203) and the No Propofol group (n=64). 
Patient characteristics are reported in Table A1. The groups only differed significantly in 
pre-operative permanent pacemaker (PPM), where the Propofol group had a lower rate of 
pre-operative PPM (10.8% versus 23.4%; p = 0.021). To detect any era effect, the 
distribution of cases by procedure date was examined. There was no significant difference 
in the distribution of cases over time between the groups (Kolmogorov-Smirnov test, p = 
0.19, Fig. 2). 
 
Table A1 - Propofol vs. No Propofol 
Baseline Patient Characteristics 
 Propofol group 
(n=203) 
No Propofol 
group (n=64)  P Value 
Age (years) 82.5 ± 8.1 83.0 ± 8.8  0.68 
Male sex 111 (54.7%) 38 (59.4%)  0.56 
BMI (kg/m2) 28.0 ± 5.6 28.9 ± 6.3  0.27 
STS Risk of Mortality Score 6.2 ± 3.9 6.6 ± 5.0  0.56 
Hypertension 175 (86.2%) 54 (84.3%)  0.69 
Diabetes 70 (34.5%) 26 (40.6%)  0.38 
Currently on dialysis 5 (2.5%) 1 (1.6%)  >0.99 
Peripheral arterial disease 38 (18.7%) 10 (15.6%)  0.71 





Prior Stroke 17 (8.4%) 5 (7.8%)  >0.99 
Immunocompromised 28 (13.8%) 3 (9.7%)  0.07 
Chronic lung disease 37 (18.2%) 8 (12.5%)  0.34 
Current or former smoker 126 (62.1%) 36 (56.3%)  0.46 
Home oxygen 12 (5.9%) 1 (1.6%)  0.20 
Atrial fibrillation 71 (35.0%) 23 (35.9%)  0.88 
Atrial flutter 8 (3.9%) 5 (7.8%)  0.31 
Conduction defect 55 (27.1%) 20 (31.3%)  0.53 
Permanent pacemaker 22 (10.8%) 15 (23.4%)  0.02 * 
Diseased coronary vessels - none 90 (44.3%) 25 (39.1%)  
0.17      Diseased coronary vessels - 1 49 (24.1%) 14 (21.9%)       Diseased coronary vessels - 2 37 (18.2%) 9 (14.1%)  
     Diseased coronary vessels - 3 27 (13.3%) 16 (25%)  
Diseased proximal LAD  51 (25.1%) 23 (35.9%)  0.11 
Diseased left main coronary artery 16 (7.9%) 11 (17.2%)  0.054 
Prior myocardial infarction 55 (27.1%) 13 (20.3%)  0.33 
Prior PCI 70 (34.5%) 23 (35.9%)  0.88 
Prior coronary artery bypass 46 (22.7%) 18 (29.7%)  0.32 
NYHA Class II  29 (14.3%) 14 (21.9%)  
0.31      NYHA Class III  148 (72.9%) 44 (68.8%)  
     NYHA Class IV  26 (12.8%) 6 (9.4%)  
Prior aortic valve replacement 18 (8.9%) 3 (4.7%)  0.42 
Elective procedure 188 (92.6%) 60 (93.75%)  >0.99      Urgent procedure 15 (7.4%) 4 (6.25%)  
No anginal symptoms 172 (84.7%) 54 (84.4%)  
0.99      Angina, NSTEMI, STEMI 10 (4.9%) 3 (4.7%)  
     Likely non-ischemic symptoms 21 (10.3%) 7 (10.9%)  
Pre-procedure hemoglobin (g/dL) 11.9 ± 1.7 11.9 ± 2.1  0.90 
Pre-procedure creatinine (mg/dL) 1.2 ± 0.9 1.1 ± 0.3  0.13 
Pre-procedure platelets (per µL) 210k ± 93k 209k ± 78k  0.90 
TAVR, Transcatheter Aortic Valve Replacement; CS, Conscious Sedation; BMI, Body Mass Index; STS, 
Society of Thoracic Surgeons; TIA, Transient Ischemic Attack; LAD, Left Anterior Descending coronary 
artery; PCI, Percutaneous Coronary Intervention; NYHA Class, New York Heart Association classification 
































































     
 
Figure 2:  TAVR Cases over 
time for Propofol versus No 
Propofol. Absolute case numbers 
varied over time in both groups, 
but the distributions of cases 
were not significantly different 






Procedural characteristics are presented in Table A2. All TAVR procedures were 
completed from a femoral entry site, via either percutaneous or cut-down access. 2% of 
procedures in the Propofol group were completed with cutdown access, and none of 
procedures in the No Propofol group were completed with cutdown (p = 0.58, Table A2). 
A significantly lower percentage of Propofol group was treated with dexmedetomidine 
(21.7% versus 65.6%, p <0.0001) and with remifentanil (13.3% versus 40.6%, p <0.0001, 
Table A2). To investigate whether medication doses also differed between the groups, 
doses were calculated according to the method used by Chen et al.42 Doses of each 
medication were plotted by group (Figure 3)B. Only remifentanil doses differed 
significantly between the groups, where the Propofol group received lower doses of 
remifentanil (mean dose 1.17 mcg/kg/hr versus 2.34 mcg/kg/hr, p = 0.0024).
 
Table A2 - Propofol vs. No Propofol 
Summary Statistics of Procedural Characteristics  
 Propofol (n=203) No Propofol (n=64)  P Value 
Valve-in-valve procedure 12 (5.9%) 2 (3.1%)  0.53 
Percutaneous Access 199 (98%) 64 (100%)  0.58      Cutdown Access 4 (2%) 0  
Treated with propofol 203 (100%) 0  - 
     Propofol dose (mg/kg/hr) 1.03 ± 0.7 -  - 
Treated with midazolam 79 (38.9%)  26 (40.6%)  0.88 
     Midazolam dose (mcg/kg/hr) 7.0 ± 3.9 6.8 ± 3.6  0.65 
Treated with dexmedetomidine 42 (20.7%)  42 (65.6%)  <0.0001 * 
     Dexmedetomidine dose (mcg/kg/hr) 0.38 ± 0.2 0.41 ± 0.2  0.065 
Treated with fentanyl 171 (84.2%)  54 (84.4%)  >0.99 
     Fentanyl dose (mcg/kg/hr) 0.42 ± 0.3 0.42 ± 0.3  0.56 
Treated with remifentanil 27 (13.3%)  26 (40.6%)  <0.0001 * 
     Remifentanil dose (mcg/kg/hr) 1.2 ± 1.0 2.3 ± 1.5  0.002 * 
 
 
B Because the doses were normalized to anesthesia time rather than total medication infusion time, the 










































































































Analysis A: Unadjusted outcomes 
Unadjusted outcomes are shown in Table A3a. Total anesthesia time did not differ 
significantly between the groups (202 versus 195 minutes, p = 0.27), and no procedures 
were aborted. There were 2 conversions to GA, with 1 conversion in the Propofol group 
(0.5%) and 1 in the No Propofol group (1.6%, p = 0.42). The patient who was converted to 
GA in the Propofol group was an 84-year-old female who became hypotensive and 
bradycardic during the procedure, requiring epinephrine and a brief period of 
cardiopulmonary resuscitation. She was converted to GA when she was intubated for 
stabilization. For the case in the No Propofol group, a 91-year-old male was noted to have 
hypercarbia and converted to GA for intubation. No procedures were converted to surgical 
valve replacement. There was no significant difference in in-hospital mortality (0.5% 
Figure 3: Comparison of medication doses between the Propofol 
versus No Propofol group. The Kolmogorov-Smirnov test was used to 





versus 1.6%, p = 0.42) or in discharge location (81.3% versus 79.7% discharged to home 
or nursing home, p = 0.85). 
 
Table A3a - Propofol vs. No Propofol 
Unadjusted, Descriptive Statistics of Peri- and Postoperative Outcomes 
 Propofol (n=203) No Propofol (n=64)  P Value 
Total anesthesia time (minutes) 202 ± 45 195 ± 33  0.27 
Conversion to general anesthesia 1 (0.5%) 1 (1.6%)  0.42 
Conversion to surgical replacement 0 0  - 
Procedure aborted 0 0  - 
Deceased in-hospital 2 (1.0%) 1 (1.6%)  0.42 
Discharged to hospice 1 (0.5%) 0  >0.99 
Home or nursing home  165 (81.3%) 51 (79.7%)  
>0.99       Rehab/extended care/ 
      transitional care unit 35 (17.2%) 12 (18.8%) 
 
 
Specific attention was paid to patients with prolonged LOS after TAVR (> 4 days), 
which is associated with all-cause mortality and worse outcomes at 1-year post-TAVR.39 
Chart review was conducted for patients with LOS > 4 days, and unadjusted results are 
shown in Table A3b. There was no significant difference in the percentage of patients who 
had prolonged LOS between the Propofol versus No Propofol groups, and there were no 
significant associations between medication group and incidence of specific causes of 
prolonged hospitalization. 
 
Table A3b - Propofol vs. No Propofol (Patients with LOS > 4 days) 
Unadjusted, Descriptive Statistics of Postoperative Complications  
 Propofol (n=43) No Propofol (n=13)  P value 
Incidence of LOS > 4 days 43 (21.2%) 13 (20.3%)  >0.99 
     Fluid overload 13 (30.2%) 6 (46.2%)  0.33 
     Hypotension 12 (27.9%) 3 (23.1%)  >0.99 
     Heart block 12 (27.9%) 5 (38.5%)  0.50 
     PPM Placement 11 (25.6%) 5 (38.5%)  0.49 
     Bleeding 9 (20.9%) 3 (23.1%)  >0.99 
     Elevated creatinine 8 (18.6%) 2 (15.4%)  >0.99 
     Infection 8 (18.6%) 2 (15.4%)  >0.99 
     New arrhythmia 4 (9.3%) 1 (7.7%)  >0.99 
     Delirium 4 (9.3%) 1 (7.7%)  >0.99 





     Hypertension 3 (7.0%) 0  >0.99 
     TIA 2 (4.7%) 0  >0.99 
     Urinary retention 2 (4.7%) 1 (7.7%)  0.55 
     Diarrhea 1 (2.3%) 1 (7.7%)  0.41 
     Pseudogout 1 (2.3%) 0  >0.99 
     Limb ischemia 1 (2.3%) 0  >0.99 
 
Analysis A: Adjusted Outcomes 
Linear regression analysis was conducted to adjust for the significantly different 
baseline characteristics when assessing for association between the Propofol group and 
continuous variable outcomes. Results are shown in Table A4. One patient in the Propofol 
group had a LOS of 32 days (shown in Fig. 4) and was excluded as an outlier from the LOS 
analysis. When controlling for pre-operative PPM, treatment with dexmedetomidine, and 
remifentanil dose, the Propofol group was not significantly associated with a change in 
hospital LOS (Coefficient 0.5 days, 95%CI: [-0.2, 1.2], p = 0.15), change in creatinine from 
pre- to post-procedure (Coefficient 0.04 mg/dL, 95%CI: [-0.1, 0.2], p = 0.60), change in 
hemoglobin pre- to post-procedure (Coefficient -0.4 g/dL, 95%CI: [-0.9, 0.06], p = 0.084), 
or creatinine at discharge (Coefficient 0.24 mg/dL, 95%CI: [-0.03, 0.5], p = 0.09).  
 
Table A4 - Propofol vs. No Propofol 
Linear Regression Analyses 
Regression 
Outcome Variable Coefficient 95% CI  P Value 
Hospital length of 




Propofol (versus No Propofol) 0.498 -0.175, 1.170  0.15 
Pre-op Permanent Pacemaker -0.104 -0.788, 0.580  0.76 
Treated with Dexmedetomidine 0.464 -0.102, 1.030  0.11 
Remifentanil Dose, mcg/kg/hr -0.079 -0.359, 0.202  0.58 
Change in 
Creatinine, pre to 
post-procedure 
(mg/dL) 
Propofol 0.038 -0.104, 0.180  0.60 
Pre-op Permanent Pacemaker -0.041 -0.186, 0.104  0.57 
Treated with Dexmedetomidine 0.046 -0.074, 0.166  0.45 
Remifentanil Dose, mcg/kg/hr -0.028 -0.087, 0.031  0.35 
Change in 
Hemoglobin, pre to 
post-procedure 
(g/dL) 
Propofol -0.415 -0.887, 0.057  0.084 
Pre-op Permanent Pacemaker -0.030 -0.510, 0.450  0.90 
Treated with Dexmedetomidine -0.211 -0.608, 0.186  0.30 







Propofol 0.239 -0.035, 0.513  0.09 
Pre-op Permanent Pacemaker -0.008 -0.286, 0.270  0.95 
Treated with Dexmedetomidine 0.150 -0.080, 0.379  0.20 













       
 
 
Logistic regression analysis was used to assess the association of the Propofol 
group with binary outcomes while adjusting for different baseline characteristics. 
Regression results are shown in Table A5. Inclusion in the Propofol group was not 
significantly associated with incidence of post-operative PPM (Odds Ratio 3.4, 95%CI: 
[0.3, 91.6], p = 0.36, Table A5) or need for red blood cell (RBC) transfusion post-
operatively (OR 1.1, 95%CI: [0.3, 5.0], p = 0.89). For the analysis of post-operative PPM, 
37 patients were excluded, because they had pre-operative PPMs (Propofol group n=22, 
10.8% versus n=15, 23.4%, Table A1). Lastly, Cox proportional hazard analysis was used 
to test for any association of MAC medication group with mortality while adjusting for 
baseline differences. Results are shown in Table A6. There was no significant association 
Figure 4: Comparison of length of stay 
for all MAC patients. All MAC cases 
(n=272) were plotted by total LOS. One 
outlier was identified (blue dot, LOS = 32 
days). This outlier was a patient who was 
treated with propofol and midazolam, and 
this patient was excluded from regression 
analysis for LOS in Analysis A, B, and C. 
Excluding the outlier: mean LOS, 2.9 days; 
Standard Deviation, 1.9 days. Median LOS, 





between the Propofol group and mortality compared to the No Propofol group (Hazard 
Ratio 1.1, 95%CI: [0.5, 2.3], p = 0.81, Table A6). 
 
Table A5 - Propofol vs. No Propofol 




Ratio 95% CI  P Value 
Post-operative PPM, 
excluding pre-
existing PPM (n= 
230) 
Propofol (versus No Propofol) 0.733 0.242, 2.312  0.58 
Treated with Dexmedetomidine 0.706 0.260, 1.729  0.47 
Remifentanil Dose, mcg/kg/hr 0.674 0.328, 1.115  0.19 
RBC transfusion 
Propofol 1.105 0.286, 4.991  0.89 
Pre-op Permanent Pacemaker 1.135 0.249, 3.749  0.85 
Treated with Dexmedetomidine 0.731 0.203, 2.213  0.60 
Remifentanil Dose, mcg/kg/hr 0.966 0.470, 1.617  0.91 
 
Table A6 - Propofol vs. No Propofol 




Ratio 95% CI  P Value 
Mortality 
Propofol (versus No Propofol) 1.095 0.527, 2.276  0.81 
Pre-op Permanent Pacemaker 0.579 0.243, 1.378  0.22 
Treated with Dexmedetomidine 1.382 0.771, 2.475  0.28 
Remifentanil Dose, mcg/kg/hr 0.867 0.596, 1.262  0.46 
 
 
Analysis B: Propofol plus midazolam versus Propofol only 
The Propofol plus midazolam group (n=70) and Propofol only group (n=94) were 
isolated for the second analysis. Patient characteristics are reported in Table B1. There 
were several characteristics that were significantly different between groups: the Propofol 
plus midazolam group was younger (78.8 ± 8.3 years versus 85.9 ± 6.0 years; p < 0.0001), 
had higher body mass index (BMI, 30.0 ± 5.7 versus 27.1 ± 5.1; p = 0.0009), had a lower 
mean STS Risk of Mortality Score (5.3 ± 3.7 versus 6.4 ± 5.3; p = 0.039), lower prevalence 
of atrial fibrillation (25.7% versus 48.9%; p = 0.004), and higher prevalence of previous 
myocardial infarction (35.7% versus 17.0%; p = 0.01). There was no significant difference 






Table B1 - Propofol plus midazolam vs. Propofol only 
Baseline Patient Characteristics 
 Propofol plus midazolam 
(n=70) 
Propofol only  
(n=94) 
 P Value 
Age (years) 78.8 ± 8.3 85.9 ± 6.0  <0.0001* 
Male sex 41 (44.1%) 52 (55.9%)  0.75 
BMI (kg/m2) 30.0 ± 5.7 27.1 ± 5.1  0.0009 * 
STS Risk of Mortality Score 5.3 ± 3.7 6.4 ± 5.3  0.04 * 
Hypertension 62 (88.6%) 78 (83.0%)  0.38 
Diabetes 29 (41.4%) 25 (26.6%)  0.064 
Currently on dialysis 0 2 (2.1%)  0.51 
Peripheral arterial disease 9 (12.9%) 15 (16.0%)  0.66 
Cerebrovascular disease/TIA 8 (11.4%) 7 (7.5%)  0.42 
Prior Stroke 5 (7.1%) 5 (5.3%)  0.75 
Immunocompromised 10 (14.3%) 11 (11.7%)  0.64 
Chronic lung disease 11 (15.7%) 18 (19.2%)  0.68 
Current or former smoker 46 (65.7%) 55 (58.5%)  0.42 
Home oxygen 4 (5.7%) 3 (3.2%)  0.46 
Atrial fibrillation 18 (25.7%) 46 (48.9%)  0.004 * 
Atrial flutter 4 (5.7%) 3 (3.2%)  0.46 
Conduction defect 14 (20.0%) 30 (31.2%)  0.11 
Permanent pacemaker 4 (5.7%) 14 (14.9%)  0.08 
Diseased coronary vessels - none 32 (45.7%) 41 (43.6%)  
0.70      Diseased coronary vessels - 1 19 (27.1%) 21 (22.3%)       Diseased coronary vessels - 2 9 (12.9%) 18 (19.1%)  
     Diseased coronary vessels - 3 10 (14.3%) 14 (14.9%)  
Diseased proximal LAD  19 (27.1%) 26 (27.6%)  >0.99 
Diseased left main coronary artery 5 (7.1%) 7 (7.5%)  >0.99 
Prior myocardial infarction 25 (35.7%) 16 (17.0%)  0.01 * 
Prior PCI 22 (31.4%) 36 (38.3%)  0.41 
Prior coronary artery bypass 18 (25.7%) 17 (18.1%)  0.25 
NYHA Class II  15 (21.4%) 10 (10.6%)  
0.16      NYHA Class III  47 (67.1%) 71 (75.5%)  
     NYHA Class IV  8 (11.4%) 13 (13.8%)  
Prior aortic valve replacement 6 (8.6%) 8 (8.5%)  >0.99 
Elective procedure 64 (91.4%) 88 (93.6%)  0.76 
     Urgent procedure 6 (8.6%) 6 (6.4%)   
No anginal symptoms 58 (82.9%) 80 (85.1%)  
0.72      Angina, NSTEMI, STEMI 7 (10%) 10 (10.6%)  
     Likely non-ischemic symptoms 5 (7.1%) 4 (4.3%)  
Pre-procedure hemoglobin (g/dL) 12.1 ± 1.6 11.7 ± 1.8  0.17 
Pre-procedure creatinine (mg/dL) 1.2 ± 0.6 1.2 ± 0.8  0.99 




































































       
 
Procedural characteristics are presented in Table B2. Cutdown procedures were 
only conducted in the Propofol group (n=2, 2.1%, p = 0.51). A significantly lower 
percentage of patients in the Propofol plus midazolam group were treated with remifentanil 
(8.6% versus 22.3%; p = 0.02, Table B2), and the Propofol plus midazolam group was 
treated with a significantly higher dose of fentanyl (mean dose 0.52 mcg/kg/hr versus 0.35 
mcg/kg/hr, p = 0.0002, Fig. 6). All other medications and doses were not significantly 
different. 
 
Table B2 – Propofol plus midazolam vs. Propofol 
Summary Statistics of Procedural Characteristics 




 P Value 
Valve-in-valve procedure 3 (4.3%) 6 (6.4%)  0.73 
Percutaneous Access 70 (100%) 92 (97.9%)  0.51      Cutdown Access 0 2 (2.1%)  
Treated with propofol 70 (100%) 94 (100%)  - 
     Propofol dose (mg/kg/hr) 1.0 ± 0.7 1.1 ± 0.7  0.18 
Treated with midazolam 70 (100%) 0  - 
     Midazolam dose (mcg/kg/hr) 7.1 ± 4.0 -  - 
Treated with fentanyl 63 (90%) 78 (83.0%)   0.26 
     Fentanyl dose (mcg/kg/hr) 0.52 ± 0.2 0.35 ± 0.2  0.0002 * 
Treated with remifentanil 6 (8.6%) 21 (22.3%)   0.02 * 
     Remifentanil dose (mcg/kg/hr) 1.2 ± 1.4 1.2 ± 0.9  0.84 
 
Figure 5:  TAVR Cases over 
time for Propofol plus 
Midazolam versus Propofol. 
The distributions of cases 
over time were not 
significantly different 

















































































Analysis B: Unadjusted outcomes 
Unadjusted procedure outcomes are shown in Table B3a. Total anesthesia time was 
not significantly different between the groups. There was 1 conversion to GA in the 
Midazolam plus Propofol group (1.4%), and there was no significant difference in in-
hospital mortality (1.4% versus 1.1%, p > 0.99). There was also no difference in discharge 
locations between the groups (82.9% versus 79.8% discharged to home or nursing home, 
p = 0.53).  
 
Table B3a – Propofol plus midazolam vs. Propofol only 
Unadjusted, Descriptive Statistics of Peri- and Postoperative Outcomes 




 P Value 
Total anesthesia time (minutes) 197 ± 42 200 ± 41  0.71 
Conversion to general anesthesia 1 (1.4%) 0   0.43 
Conversion to surgical replacement 0 0  - 
Procedure aborted 0 0  - 
Deceased in-hospital 1 (1.4%) 1 (1.1%)  >0.99 
Discharged to hospice 1 (1.4%) 0  0.43 
Discharged to home or nursing home  58 (82.9%) 75 (79.8%)  
>0.99       Discharged to rehab/extended 




Figure 6: Comparison of medication doses between Propofol plus Midazolam 
versus Propofol only. The Kolmogorov-Smirnov test was used to compare doses. 





Analysis of patients with LOS > 4 days is shown in Table B3b. The Propofol plus 
midazolam group had a lower percent of patients with LOS > 4 days, but the difference 
was not significant (12.9% versus 24.5%, p = 0.075, Table B3b). Since this analysis was 
unadjusted, the association between the medication groups and prolonged LOS was also 
tested using logistic regression to adjust for different baseline variables (Table B5). In the 
adjusted analysis, the association remained non-significant (Odds Ratio 0.85, 95%CI: [0.3, 
2.4], p = 0.78). Additionally, the Propofol plus midazolam group had a higher percentage 
of patients who experienced hypotension as part of the cause of their prolonged length of 
stay (55.5% versus 17.4%, p = 0.075, Table B3b). This association was also tested with 
adjustment (Table B5), and the association remained non-significant (Odds Ratio 5.8, 
95%CI: [0.6, 81.6], p = 0.14, Table B5). 
 
Table B3b – Propofol plus midazolam vs. Propofol only (Patients with LOS > 4 days) 
Unadjusted, Descriptive Statistics of Postoperative Complications 
 Propofol plus midazolam 
(n=9) 
Propofol only 
(n=23)  P Value 
Incidence of LOS > 4 days 9 (12.9%) 23 (24.5%)  0.075 
     Hypotension 5 (55.5%) 4 (17.4%)  0.075 
     Fluid overload 3 (33.3%) 5 (21.8%)  0.65 
     Elevated creatinine 3 (33.3%) 3 (13.0%)  0.31 
     Heart block 3 (33.3%) 6 (26.1%)  0.69 
     PPM Placement 3 (33.3%) 5 (21.8%)  0.65 
     Infection 2 (22.2%) 4 (17.4%)  >0.99 
     Stroke 2 (22.2%) 1 (4.3%)  0.18 
     Bleeding 1 (11.1%) 6 (26.1%)  0.64 
     Hypertension 1 (11.1%) 2 (8.7%)  >0.99 
     Delirium 1 (11.1%) 1 (4.3%)  0.49 
     Limb ischemia 1 (11.1%) 0  0.28 
     New arrhythmia 0 2 (8.7%)  >0.99 
     Urinary retention 0 2 (8.7%)  >0.99 
     TIA 0 1 (4.3%)  >0.99 








Analysis B: Adjusted Outcomes 
The effect of the medication groups on continuous variable outcomes was assessed 
using linear regression analysis to control for significantly different baseline 
characteristics. Regression results are shown in Table B4. One patient in the Propofol plus 
midazolam group had a LOS of 32 days and was excluded as an outlier (shown previously 
in Fig. 4). Compared to the Propofol only group, Propofol plus midazolam was not 
associated with LOS (Coefficient 0.2 days, 95%CI: [-0.5, 0.8], p = 0.62), change in 
creatinine (Coefficient -0.02 mg/dL, 95%CI: [-0.2, 0.1], p = 0.85), change in hemoglobin 
(Coefficient -0.06 g/dL, 95%CI: [-0.5, 0.7], p = 0.64), or creatinine at discharge 
(Coefficient -0.04 mg/dL, 95%CI: [-0.3, 0.2], p = 0.76). Conversely, other variables in the 
model were significantly association with several outcomes. First, a 1% increase in STS 
Risk Score was associated with a 0.13 day increased in LOS (Coefficient 0.13 days, 
95%CI: [0.05, 0.2], p = 0.002). Second, a 1 kg/m2 increase in body mass index (BMI) was 
associated with a 0.015 mg/dL increase in creatinine post-operatively (Coefficient 0.015 
mg/dL, 95%CI: [0.003, 0.03], p = 0.016) and a 0.028 mg/dL increase in discharge 
creatinine (Coefficient 0.028 mg/dL, 95%CI: [0.008, 0.048], p = 0.007).  
 
Table B4 - Propofol plus midazolam vs. Propofol only 
Linear Regression Analyses 
Regression 
Outcome Variable Coefficient 95% CI 
 P Value 
Hospital length 







Propofol plus midazolam 
(versus Propofol only) 0.169 -0.506, 0.843  0.62 
Age 0.021 -0.019, 0.062  0.31 
BMI 0.003 -0.048, 0.055  0.90 
STS Risk Score 0.126 0.047, 0.206  0.002 * 
Atrial fibrillation -0.095 -0.666, 0.476  0.74 
Prior myocardial infarction -0.278 -0.919, 0.364  0.39 
Treated with Remifentanil 0.459 -0.309, 1.226  0.24 
Fentanyl Dose (mcg/kg/hr) -0.575 -1.783, 0.633  0.35 
Change in 
Creatinine, pre to 
Propofol plus midazolam -0.016 -0.177, 0.145  0.85 







BMI 0.015 0.003, 0.028  0.016 * 
STS Risk Score 0.011 -0.008, 0.030  0.25 
Atrial fibrillation -0.052 -0.189, 0.085  0.46 
Prior myocardial infarction 0.048 -0.105, 0.202  0.53 
Treated with Remifentanil 0.009 -0.175, 0.193  0.92 






Propofol plus midazolam 0.063 -0.526, 0.652  0.83 
Age -0.026 -0.062, 0.010  0.16 
BMI -0.027 -0.073, 0.0182  0.24 
STS Risk Score 0.035 -0.035, 0.105  0.33 
Atrial fibrillation 0.326 -0.176, 0.827  0.20 
Prior myocardial infarction 0.004 -0.558, 0.566  0.99 
Treated with Remifentanil -0.546 -1.220, 0.129  0.11 




Propofol plus midazolam -0.040 -0.304, 0.224  0.76 
Age -0.004 -0.020, 0.012  0.61 
BMI 0.028 0.008, 0.048  0.007 * 
STS Risk Score 0.028 -0.004, 0.059  0.08 
Atrial fibrillation 0.030 -0.195, 0.255  0.79 
Prior myocardial infarction -0.047 -0.299, 0.204  0.71 
Treated with Remifentanil -0.007 -0.312, 0.298  0.96 
Fentanyl Dose (mcg/kg/hr) -0.133 -0.606, 0.339  0.58 
 
 
Logistic regression analysis was used to assess for association between Propofol 
plus midazolam and binary outcomes of interest. Regression results are shown in Table B5. 
Propofol plus midazolam was not significantly associated with post-operative PPM (Odds 
Ratio 1.0, 95%CI: [0.3, 3.1], p = 0.94) or with RBC transfusion (OR 1.2, 95%CI: [0.3, 5.0], 
p = 0.83). 18 patients had pre-operative permanent PPMs and were excluded from the 
analysis of post-operative PPM (n=4, 5.7% and n=14, 14.9%, p = 0.08, Table B1). 
However, there was a significant association between STS Risk Score and post-operative 
RBC transfusion (OR 1.2, 95%CI: [1.05, 1.40], p = 0.008). Additionally, STS Risk Score 
was associated with increased odds of LOS > 4 days (OR 1.21, 95%CI: [1.07, 1.34], p = 







Table B5 - Propofol plus midazolam vs. Propofol only 
Logistic Regression Analyses 
Outcome Variable Odds Ratio 95% CI  P Value 
Post-operative PPM, 
excluding pre-
existing PPM (n= 
164) 
Propofol plus midazolam 
(versus Propofol only) 1.041 0.336, 3.137 
 0.94 
Age 0.990 0.928, 1.059  0.76 
BMI 1.044 0.962, 1.134  0.30 
STS Risk Score 0.977 0.830, 1.113  0.76 
Atrial fibrillation 0.843 0.305, 2.192  0.73 
Prior myocardial infarction 1.049 0.330, 3.007  0.93 
Treated with Remifentanil 1.068 0.262, 3.677  0.92 
Fentanyl Dose (mcg/kg/hr) 0.732 0.091, 4.996  0.76 
RBC transfusion 
Propofol plus midazolam 1.176 0.256, 5.023  0.83 
Age 1.019 0.936, 1.118  0.67 
BMI 1.065 0.950, 1.196  0.28 
STS Risk Score 1.205 1.054, 1.401  0.008 * 
Atrial fibrillation 0.400 0.093, 1.414  0.18 
Prior myocardial infarction 1.333 0.314, 4.983  0.68 
Treated with Remifentanil 3.818 0.894, 15.93  0.063 
Fentanyl Dose (mcg/kg/hr) 0.499 0.030, 6.330  0.61 




Propofol plus midazolam 
(versus Propofol only) 0.845 0.279, 2.417  0.78 
Age 1.012 0.947, 1.085  0.73 
BMI 0.983 0.904, 1.067  0.69 
STS Risk Score 1.205 1.068, 1.377  0.004 * 
Atrial fibrillation 0.550 0.210, 1.359  0.21 
Prior myocardial infarction 0.422 0.112, 1.283  0.16 
Treated with Remifentanil 2.460 0.842, 7.027  0.09 




LOS, n=9 versus 
n=23) † 
 
Propofol plus midazolam 
(versus Propofol only) 5.790 0.632, 81.60  0.14 
Age 0.920 0.790, 1.056  0.23 
BMI 0.940 0.740, 1.148  0.56 
STS Risk Score 0.842 0.592, 1.065  0.25 
Atrial fibrillation 0.236 0.011, 2.091  0.24 
Prior myocardial infarction 0.636 0.009, 22.73  0.82 
† Input variables for Remifentanil treatment and Fentanyl dose were removed, because the model did not 
converge. 
 
Cox proportional hazard analysis found no association between the Propofol plus 
midazolam group and mortality compared to the Propofol only group (Hazard Ratio 0.5, 
95%CI: [0.2, 1.2], p = 0.13). Other variables did demonstrate significant association with 





death (HR 1.12, 95%CI: [1.0, 1.2], p = 0.003), and atrial fibrillation was associated with a 
128% increase in hazard of death (HR 2.28, 95%CI: [1.1, 4.8], p = 0.03). 
 
Table B6 - Propofol plus midazolam vs. Propofol only 
Cox Proportional Hazard Model Outcomes 
Outcome Variable Hazard Ratio 95% CI 
 P Value 
Mortality 
Propofol plus midazolam 0.510 0.212, 1.226  0.13 
Age 1.049 0.991, 1.111  0.10 
BMI 1.031 0.962, 1.104  0.39 
STS Risk Score 1.120 1.039, 1.206  0.003 * 
Atrial fibrillation 2.277 1.079, 4.801  0.03 * 
Prior myocardial infarction 0.935 0.413, 2.117  0.87 
Treated with Remifentanil 1.148 0.461, 2.862  0.77 
Fentanyl Dose (mcg/kg/hr) 0.566 0.107, 2.982  0.50 
 
 
Analysis C: Dexmedetomidine versus No Dexmedetomidine  
Lastly, the 272 CS patients were divided into the Dexmedetomidine group (n=86) 
and the No Dexmedetomidine group (n=186).  Patient characteristics are reported in Table 
C1. The groups only differed significantly in incidence of peripheral arterial disease, where 
the Dexmedetomidine group had significantly more disease burden (26.7% versus 13.4%; 
p = 0.01). Additionally, the case distribution over time differed significantly between the 
groups (p < 0.0001, Fig. 7), indicating that the procedure year needs to be taken into 
account as a potential confounding variable. 
 
Table C1 - Dexmedetomidine vs. No Dexmedetomidine group 
Baseline Characteristics of TAVR Patients 
 Dexmedetomidine 
(n=86) 
No Dex  
(n=186) 
 P Value 
Age (years) 82.3 ± 8.7 83.0 ± 8.0  0.52 
Male sex 46 (53.5%) 107 (57.5%)  0.60 
BMI (kg/m2) 27.6 ± 6.2 28.5 ± 5.6  0.28 
STS Risk of Mortality Score 6.4 ± 4.0 6.2 ± 4.1  0.72 
Hypertension 74 (87.2%) 157 (84.4%)  0.59 
Diabetes 34 (39.5%) 62 (33.3%)  0.34 
Currently on dialysis 4 (4.7%) 2 (1.1%)  0.08 





Cerebrovascular disease/TIA 8 (9.3%) 17 (9.1%)  >0.99 
Prior Stroke 11 (12.8%) 12 (6.5%)  0.10 
Immunocompromised 8 (9.3%) 23 (12.4%)  0.54 
Chronic lung disease 13 (15.1%) 32 (12.7%)  0.73 
Current or former smoker 51 (59.3%) 113 (60.8%)  0.89 
Home oxygen 6 (7.0%) 7 (3.8%)  0.36 
Atrial fibrillation 26 (30.2%) 71 (38.2%)  0.22 
Atrial flutter 5 (5.8%) 8 (4.3%)  0.56 
Conduction defect 27 (31.4%) 51 (27.4%)  0.56 
Permanent pacemaker 14 (16.3%) 24 (12.9%)  0.46 
Diseased coronary vessels - none 36 (41.9%) 81 (43.5%)  
0.30      Diseased coronary vessels - 1 15 (17.4%) 48 (25.8%)       Diseased coronary vessels - 2 18 (20.9%) 31(16.7%)  
     Diseased coronary vessels - 3 17 (19.8%) 26 (13.4%)  
Diseased proximal LAD  24 (27.9%) 53 (28.5%)  >0.99 
Diseased left main coronary artery 12 (14.0%) 15 (8.1%)  0.13 
Prior myocardial infarction 22 (25.6%) 46 (24.7%)  0.88 
Prior PCI 28 (32.6%) 66 (35.5%)  0.68 
Prior coronary artery bypass 27 (31.4%) 39 (21.0%)  0.07 
NYHA Class II  14 (16.3%) 31 (16.7%)  
0.23      NYHA Class III  66 (76.7%) 129 (69.4%)  
     NYHA Class IV  6 (7.0%) 26 (14.0%)  
Prior aortic valve replacement 5 (5.8%) 16 (8.6%)  0.48 
Elective procedure 82 (95.3%) 171 (91.9%)  0.44      Urgent procedure 4 (4.7%) 15 (8.1%)  
No anginal symptoms 75 (87.2%) 156 (83.9%)  
0.73      Angina, NSTEMI, STEMI 3 (3.5%) 10 (5.4%)  
     Likely non-ischemic symptoms 8 (9.3%) 20 (10.8%)  
Pre-procedure hemoglobin (g/dL) 12.1 ± 1.9 11.8 ± 1.8  0.30 
Pre-procedure creatinine (mg/dL) 1.2 ± 1.0 1.2 ± 0.7  0.63 






























































       
 
Procedural characteristics are presented in Table C2. Cutdown access occurred in 
both groups (2.3% versus 1.1%, p = 0.59). Several other procedural characteristics were 
significantly different: fewer patients in the Dexmedetomidine group were treated with 
Figure 7: TAVR Cases over 
time, Dexmedetomidine 
versus No Dexmedetomidine. 
The distributions of cases over 
time significantly different 






propofol (50% versus 88.2%, p <0.0001) and remifentanil (13.3% versus 40.6%, p 
<0.0001), and propofol doses were significantly lower in the Dexmedetomidine group 
(mean dose 0.76 mcg/kg/hr versus 1.1 mcg/kg/hr, p = 0.0024, Fig. 8).  
 
Table C2 – Dexmedetomidine vs. No Dexmedetomidine group 
Summary Statistics of TAVR Procedural Characteristics 
 Dexmedetomidine 
(n=86) 
No Dex  
(n=186) 
 P Value 
Valve-in-valve procedure 4 (4.7%) 10 (5.4%)  >0.99 
Percutaneous Access 84 (97.7%) 184 (98.9%)  0.59      Cutdown Access  2 (2.3%) 2 (1.1%)  
Treated with propofol 43 (50%) 164 (88.2%)  <0.0001 * 
     Propofol dose (mg/kg/hr) 0.76 ± 0.7 1.1 ± 0.7  0.006 * 
Treated with midazolam 25 (29.1%)  74 (39.8%)  0.10 
     Midazolam dose (mcg/kg/hr) 6.7 ± 3.5 7.1 ± 4.0  0.70 
Treated with dexmedetomidine 86 (100%) 0  - 
     Dexmedetomidine dose (mcg/kg/hr) 0.40 ± 0.2 -  - 
Treated with fentanyl 68 (79.1%)  162 (87.1%)  0.10 
     Fentanyl dose (mcg/kg/hr) 0.41 ± 0.3 0.42 ± 0.2  0.08 
Treated with remifentanil 13 (15.1%)  42 (22.6%)  0.19 








































































































test was used to 








Analysis C: Unadjusted outcomes 
Unadjusted procedure outcomes are shown in Table C3a. Total anesthesia time 
did not differ significantly between the groups (204 minutes versus 198, p = 0.25). No 
patients were converted to GA in the Dexmedetomidine group, and 2 were converted in 
the No Dexmedetomidine group (p > 0.99). There was no difference in in-hospital 
mortality (1.2% versus 0.5%, p = 0.53) or in discharge location (81.4% discharged to 
home or nursing home versus 81.4%, p > 0.99). There was also no difference in the 
percent of patients who experienced prolonged LOS (23.3% versus 19.9%, p = 0.53, 
Table C3b), and there were no differences in the incidence of specific causative 
complications. 
 
Table C3a – Dexmedetomidine vs. No Dexmedetomidine 
Unadjusted, Descriptive Statistics of Peri- and Postoperative Outcomes 
 Dexmedetomidine  
(n=86) 
No Dexmedetomidine  
(n=186) 
 P Value 
Total anesthesia time (minutes) 204 ± 48 198 ± 40  0.25 
Conversion to general anesthesia 0 2 (1.1%)  >0.99 
Conversion to surgical replacement 0 0  - 
Procedure aborted 0 0  - 
Deceased in-hospital 1 (1.2%) 2 (1.1%)  >0.99 
Discharged to hospice 0 2 (1.1%)  - 
Discharged to home or nursing home  70 (81.4%) 149 (80.1%)  
>0.99       Discharged to rehab/extended 
      care/transitional care unit 15 (17.4%) 34 (18.3%) 
 
 
Table C3b – Dexmedetomidine vs. No Dexmedetomidine (Patients with LOS > 4 days) 
Unadjusted, Descriptive Statistics of Postoperative Complications 
 Dexmedetomidine  (n=20) 
No Dexmedetomidine  
(n=37) 
 P Value 
Incidence of LOS > 4 days 20 (23.3%) 37 (19.9%)  0.53 
     Hypotension 4 (20%) 11 (29.7%)  0.54 
     Fluid overload 9 (45%) 10 (27.0%)  0.24 
     Elevated creatinine 3 (15%) 7 (18.9%)  >0.99 
     Heart block 6 (30%) 11 (29.7%)  >0.99 
     PPM Placement 6 (30%) 10 (27.0%)  >0.99 
     Infection 3 (15%) 7 (18.9%)  >0.99 
     Stroke 1 (5%) 3 (8.1%)  >0.99 





     Hypertension 1 (5%) 2 (5.4%)  >0.99 
     Delirium 3 (15%) 2 (5.4%)  0.33 
     New arrhythmia 3 (15%) 2 (5.4%)  0.33 
     Pseudogout 1 (5%) 0  0.35 
     Diarrhea 1 (5%) 1 (2.7%)  >0.99 
     Urinary retention 0 3 (8.1%)  0.54 
     TIA 0 1 (2.7%)  >0.99 
     Limb ischemia 0 1 (2.7%)  >0.99 
 
Analysis C: Adjusted Outcomes 
Linear regression was used to assess for association between the Dexmedetomidine 
group and continuous variable outcomes. Results are show in Table C4. One patient in the 
No Dexmedetomidine group had a LOS of 32 days and was excluded as an outlier (shown 
previously in Fig. 4). Inclusion in the Dexmedetomidine group was not significantly 
associated with hospital LOS (Coefficient -0.1 days, 95%CI: [-0.9, 0.6], p = 0.71, Table 
C4), post-operative change in creatinine (Coefficient -0.01 mg/dL, 95%CI: [-0.1, 0.1], p = 
0.84), post-operative change in hemoglobin (Coefficient -0.2 g/dL, 95%CI: [-0.7, 0.2], p = 
0.35), or creatinine at discharge (Coefficient -0.01 mg/dL, 95%CI: [-0.2, 0.2], p = 0.93). 
Conversely, peripheral arterial disease was associated with an increase in discharge 
creatinine (Coefficient 0.5 mg/dL, 95%CI: [0.3, 0.7], p = <0.0001).  
 
Table C4 - Dexmedetomidine vs. No Dexmedetomidine 
Linear Regression Analyses 
Regression 
Outcome Variable Coefficient 95% CI  P Value 
Hospital length of 
stay (days) 
(one outlier 
excluded from the 
No Dex group) 
Dexmedetomidine (versus 
No Dexmedetomidine) -0.145 -0.917, 0.626  0.71 
Peripheral arterial disease 0.195 -0.661, 1.052  0.65 
Procedure Year -0.055 -0.551, 0.441  0.83 
Propofol Dose, mg/kg/hr -0.276 -0.717, 0.164  0.22 
Change in 
Creatinine, pre to 
post-procedure 
(mg/dL) 
Dexmedetomidine -0.012 -0.134, 0.109  0.84 
Peripheral arterial disease 0.096 -0.039, 0.231  0.16 
Procedure Year -0.037 -0.115, 0.041  0.35 
Propofol Dose, mg/kg/hr 0.009 -0.061, 0.078  0.81 










Peripheral arterial disease 0.094 -0.415, 0.604  0.72 
Procedure Year -0.147 -0.442, 0.149  0.33 
Propofol Dose, mg/kg/hr 
0.060 
-0.203, 0.322  0.65 
Creatinine at 
discharge (mg/dL) 
Dexmedetomidine -0.010 -0.233, 0.214  0.93 
Peripheral arterial disease 0.498 0.250, 0.746  <0.0001 * 
Procedure Year 0.019 -0.125, 0.163  0.80 
Propofol Dose, mg/kg/hr -0.013 -0.141, 0.115  0.85 
 
 
Table C5 shows results of logistic regression analysis. The Dexmedetomidine 
group had no significant association with incidence of post-operative PPM (Odds Ratio 
0.8, 95%CI: [0.3, 1.9], p = 0.51, Table C1) or with RBC transfusion (OR 0.5, 95%CI: [0.1, 
1.6], p = 0.25). 38 patients had pre-existing PPMs and were excluded from the PPM 
analysis (n=14, 16.3% and n=24, 12.9%, Table C1). Finally, cox proportional hazard 
analysis found no association between the Dexmedetomidine group and mortality (Hazard 
Ratio 1.0, 95%CI: [0.6, 1.9], p = 0.82, Table C6). 
 
Table C5 - Dexmedetomidine vs. No Dexmedetomidine 
Logistic Regression Analyses 
Regression 
Outcome Variable Odds Ratio 95% CI  P Value 
Post-operative PPM, 
excluding pre-
existing PPM (n= 
234) 
Dexmedetomidine (versus No 
Dexmedetomidine) 0.781 0.307, 1.911  0.59 
Peripheral arterial disease 1.080 0.372, 2.747  0.88 
Procedure Year 0.991 0.563, 1.797  0.98 
Propofol Dose, mg/kg/hr 0.899 0.525, 1.483  0.68 
RBC transfusion 
Dexmedetomidine 0.511 0.148, 1.557  0.25 
Peripheral arterial disease 1.638 0.430, 5.156  0.42 
Procedure Year 1.690 0.794, 3.979  0.20 
Propofol Dose, mg/kg/hr 0.476 0.196, 0.998  0.07 
 
Table C6 - Dexmedetomidine vs. No Dexmedetomidine 
Cox Proportional Hazard Model Outcomes 
Regression 
Outcome Variable Odds Ratio 95% CI  P Value 
Mortality 
Dexmedetomidine 1.071 0.603, 1.903  0.82 
Peripheral arterial disease 1.146 0.607, 2.163  0.68 
Procedure Year 1.000 0.999, 1.000  0.57 






TAVR has rapidly become a common treatment for severe, symptomatic AS, and 
more TAVR procedures are being completed under CS instead of GA than ever before.24 
Despite growing popularity of CS or Monitored Anesthesia Care (MAC; CS administered 
by an anesthesiologist) in TAVR, there has been limited investigation into the optimal 
MAC medications for TAVR patients. The current study retrospectively analyzed 
outcomes after TAVR for three different medication group comparisons: Propofol versus 
No Propofol (Analysis A), Propofol plus midazolam versus Propofol only (Analysis B), 
and Dexmedetomidine versus No Dexmedetomidine (Analysis C). The study found that for 
each analysis, the medication group had no significant association with total hospital LOS, 
mortality, and need for PPM. Additionally, there were no significant differences between 
the groups in each analysis for secondary outcomes of interest, including: in-hospital death, 
discharge location, change in creatinine from pre- to post-procedure, change in hemoglobin 
from pre- to post-procedure, creatinine at discharge, and need for post-operative RBC 
transfusion. 
The lack of significant association between MAC medication and outcomes is 
consistent with previous findings from Khalil et al.,40 Mayr et al.,41 Chen et al.,42 and 
Kronfli et al.43 Each of these prior studies found no difference in post-operative outcomes 
between the comparator medication groups (propofol-opioid vs. dexmedetomidine; 
propofol vs. propofol plus dexmedetomidine; or propofol only vs. dexmedetomidine only). 
However, the lack of difference in these and the current study does not rule out the 





after TAVR. It is possible that a difference does exist but has not been detected due to small 
sample sizes and low frequency of events, resulting in underpowered analyses. 
Results from the current study do indicate that it is possible that propofol plus 
midazolam may be suboptimal for TAVR compared to propofol only. In Analysis B, the 
Propofol plus midazolam group had greater incidence of hypotension as a causative factor 
of prolonged LOS, although the increase in incidence was not significant in unadjusted 
analysis (55.5% versus 17.4%, p = 0.075, Table B3) or in adjusted analysis (Odds Ratio 
5.79, 95%CI: [0.63, 81.6], p = 0.14, Table B5). This is of interest despite lack of 
significance, because the Propofol plus midazolam group had a larger percentage of 
patients affected by hypotension leading to prolonged LOS despite having a younger and 
less ill cohort than the Propofol only group. This regimen notably combines two 
medications known to synergize and to cause cardiovascular depression, and propofol plus 
midazolam has been associated with worse outcomes in other procedures; in a randomized 
study comparing outcomes for endoscopy patients treated with propofol only (n=120) 
versus propofol plus midazolam (n=119), propofol plus midazolam resulted in significantly 
longer recovery time and a significantly lower recovery quality (based on patient scoring), 
despite achieving similar efficacy of intra-operative sedation.48 Therefore, this study 
indicates further exploration of the effects of propofol plus midazolam versus propofol only 
in MAC for TAVR may be warranted. It is possible that with a greater sample size, the 
association between Propofol plus midazolam and post-operative hypotension could 
become significant.  
Some of the baseline patient characteristics did vary significantly between the 





retrospective nature of this study. First, patients in the Propofol group had fewer pre-
existing permanent pacemakers (11% versus 23%, p = 0.02, Table A1). Anesthetic agents 
are not expected to negatively affect the function of PPMs,67 but propofol has potential to 
be pro-arrhythmic by blocking or drastically slow conduction. It is possible that providers 
may have avoided propofol in patients with pacemakers due to this potentially pro-
arrhythmic effect, but the literature linking propofol to increased risk of arrhythmias is 
mixed and lacking.52 Patients in the Propofol group were also less likely to have had left 
main coronary disease (8% versus 17%, p=0.054, Table A1). This association was likely 
because providers were wary of the effects of propofol on cardiac function and 
hemodynamic in patients with coronary artery disease (CAD). Propofol has been shown to 
reduce systolic and diastolic blood pressure, myocardial blood flow, and myocardial 
oxygen consumption in CAD patients.68-70  
Next, patients in the Propofol plus midazolam group were younger (78.8 year ± 8.3 
versus 85.9 years ± 6.0, p <0.0001, Table B1) and had lower STS risk score (5.3 ± 3.7 
versus 6.4 ± 5.3, p = 0.04, Table B1). It is possible that the association of the Propofol plus 
midazolam group with age and STS Risk Score is due to providers preferring to use a 
combination of synergistic medications in younger, potentially less sedation-sensitive 
patients. It is recognized that co-administration of propofol and midazolam results in 
increased sedative and cardio-respiratory depression effects of both medications,33,34 with 
the combination resulting in deeper sedation and more frequent deep sedation than propofol 
alone.22,44 It is also recognized that elderly patients are more sensitive to both propofol71,72 





Lastly, more patients treated in the Dexmedetomidine group had prior peripheral 
arterial disease (PAD, 26.7% versus 13.4%, p = 0.01, Table C1). This may be due to 
institutional or provider preference, since choice of MAC medications used in patients with 
PAD does not have strict guidelines.74 Kronfli et al. also had a dexmedetomidine group 
with significantly more patients with prior PAD than the propofol group (78.6% versus 
72.7%, p = 0.024), but this difference is not explained.43 There may be some advantage to 
use of dexmedetomidine over midazolam for patients with PAD; in a randomized study 
treated PAD patients with either dexmedetomidine plus remifentanil or midazolam plus 
remifentanil, patients treated with dexmedetomidine had significantly lower post-operative 
pain scores and higher satisfaction.75  
There were differences in the doses of other MAC medications received in each 
group. First, patients in the Propofol group (Analysis A) received less dexmedetomidine 
(20.7% versus 65.6%, p <0.0001, Table A2) and less remifentanil (13.3% versus 40.6%, p 
<0.0001, Table A2) than patients in the No Propofol group. This is expected, because the 
propofol group will have received propofol, reducing the need for other medications to 
achieve adequate sedation. Similarly, patients in the Propofol plus midazolam group 
(Analysis B) received less remifentanil (8.6% versus 22.3%, p = 0.02, Table B2) compared 
to patients in the Propofol only group. However, the Propofol plus midazolam group 
received more fentanyl than the Propofol only group (0.52 ± 0.2 mcg/kg/hr versus 0.35 ± 
0.2 mcg/kg/hr, p = 0.0002, Table B2). This is possibly because fewer Propofol plus 
midazolam patients received remifentanil overall (8.6% versus 22.3%), so there were more 
patients in the group who received fentanyl as the only opioid. It is possible that patient 





instead, raising the group mean dose. Lastly, fewer patients in the Dexmedetomidine group 
(Analysis C) were treated with propofol (50% versus 88.2%, p < 0.0001, Table C2), 
indicating that patients given dexmedetomidine may need and receive less propofol to 
attain adequate sedation. 
Even though the studied CS medication groups were ultimately not associated with 
outcomes of interest, other variables that were included in the regression analyses were 
significantly associated with outcomes. In Analysis B, STS Risk score was associated with 
a 0.13 day increased in LOS (Coefficient 0.13 days, 95%CI: [0.05, 0.2], p = 0.002, Table 
B4) and an increased hazard of post-operative mortality (Hazard Ratio 1.12, 95%CI: [1.04, 
1.21], p = 0.003, Table B6). Both of these associations are expected, since STS Risk Score 
is intentionally designed to predict outcomes including length of hospital stay and mortality 
after valve replacement.76 STS Risk score was also independently associated with an 
increase in post-operative blood transfusion (Odds Ratio 1.21, 95%CI: [1.05, 1.40], p = 
0.008, Table B5).  Need for post-TAVR transfusion is commonly due to intraprocedural 
vascular damage and complications leading to blood loss during and after the procedure.77 
It is possible that increase in STS Risk score leads to increased transfusion, because patients 
with higher scores are sicker and may be more susceptible to vascular injury and less 
resilient due to comorbidities and frailty.  
In Analysis B, BMI was independently associated with an increase in creatinine 
before versus after the TAVR (Coefficient 0.015 mg/dL, 95%CI: [0.003, 0.028], p = 0.016, 
Table B4) and with an increase in creatinine at discharge (Coefficient 0.028 mg/dL, 
95%CI: [0.008, 0.048], p = 0.007, Table B4). This can be explained by previous evidence 





after surgery and a greater post-procedural increase in creatinine.78-80 Additionally in 
Analysis B, atrial fibrillation was independently associated with mortality (Hazard Ratio 
2.3, 95%CI: [1.08, 4.8], p = 0.03, Table B6). This corroborates findings that patients with 
atrial fibrillation suffer from an increased risk of all-cause mortality compared to the 
general population.81,82 Lastly, in Analysis C, PAD was associated with an increase in 
discharge creatinine (Coefficient 0.5 mg/dL, 95%CI: [0.25, 0.75], p < 0.0001, Table C4). 
The increase in creatinine is likely secondary to perioperative renal hypoperfusion due to 
vascular disease. Indeed, PAD is a risk factor for acute kidney injury following surgery.83,84 
This study has several key limitations. First, this is a retrospective study, so biases 
in patient selection and distribution to MAC groups were not controlled for. Indeed, there 
were noted differences in baseline characteristics. Multivariate regression should have 
helped account for these differences, although it is still possible that unknown variables 
may have confounded the effects of recorded variables. Additionally, study data is limited 
by what was recorded accurately in the chart. Next, this analysis did not take into account 
patient ASA score (I-VI), which may have contributed to provider decision-making in 
choosing a MAC regimen. Next, the sample size for the current study was still relatively 
small, and effects of medication groups may be hidden by underpowered analyses. The 
sample sizes were limited by heterogeneity of medication combinations used in the 
surveyed sample. Lastly, Analysis A and Analysis C were comparisons of aggregate 
groups, meaning patients in the Propofol group for Analysis A could also have been treated 
with dexmedetomidine or midazolam. While the analysis accounted for frequency and dose 
of other medications to control for this additional variable, this adjustment may not have 





 In this single institution patient population, MAC medication group was not 
significantly associated with outcomes of interest, including total hospital LOS, mortality, 
and need for post-operative PPM. These findings suggest that within MAC, specific 
medication choice may not significantly affect clinically impactful outcomes after TAVR. 
However, it is still possible that a difference exists and requires a larger cohort to be 
detected. Further investigation is warranted, because even small improvements in 
outcomes related to MAC medications could be magnified and generate tangible gains in 
quality and cost of TAVR patient care. In particular, testing of propofol plus midazolam 
versus propofol only or midazolam only is warranted, because propofol plus midazolam 
may prolong recovery and resulting hospital LOS due to synergistic cardiovascular 
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